Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

vTv Therapeutics Inc.

35 indications, side-by-side phase, drug & LoA

$32.77

+1.18 (+3.72%)

B 78Pipeline Score Undervalued Pharma · Clinical
Market Cap
135.52 M
EPS
-0.63
P/E Ratio
-
Value Trade
779.51 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    36.84 M

  • R&D Expenses

    8.98 M

  • Operating CF

    9.15 M

  • Total Assets

    98.81 M

  • Total Liabilities

    8.85 M

  • Equity

    89.96 M

  • D/E Ratio

    12,345

-10.29 %
Week
-11.78 %
1 Month
-2.92 %
3 Month
13.81 %
6 Month
-65.18 %
5 Year
-93.86 %
All Time
Cash Data
Profitable

  • Cash Position

    98.09 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    May 13, 2026
Overview
Volume
60.73 K
52 Week Range
14 - 44
% held by Insiders
48.11 %
% held by Institutions
30.16 %
Enterprise Value
37.43 M
Total Shares
3.94 M
Short %
7.71 %
Float Shares
1.59 M
Company Description
HQ: 3980 PREMIER DR, HIGH POINT, N...
Employees:26
https://www.vtvtherapeutics.co...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
Cadisegliatin (TTP399) Type 1 diabetes (T1D)
Phase 3
—
Small Molecules
Endocrine System
Cadisegliatin (TTP399) Type 1 diabetes (T1D)
Phase 3
—
Small Molecules
Endocrine System
Cadisegliatin (TTP399) Type 1 diabetes (T1D)
Phase 3
—
Small Molecules
Endocrine System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B78
Pipeline Score
$2.0B
Pipeline Value
Undervalued
Valuation Signal
8
Drugs Scored
15.0x
rNPV / MCap
Top 96%
Micro Cap
(rank 37 of 905)
Percentile Rank
vTv Therapeutics Inc. holds a solid B-grade pipeline (78/100), with $54.6B risk-adjusted pipeline value, led by Cadisegliatin in Diabetes Mellitus, Type 1 (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Cadisegliatin
Small molecule		Diabetes Mellitus, Type 1Phase 3NCT0633413390% $23.4B RECRUITING 150 SLOW B (74) Oct 1, 2026MODERATE_RISKLOW
Jun 2, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
cadisegliatin
type 1 diabetes
Phase 3
2025-08-08
cadisegliatin
type 1 diabetes
Phase 3
2025-08-08
cadisegliatin
type 1 diabetes
Phase 3
2025-08-08
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in VTVT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
VTVT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VTVT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
VTVT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
VTVT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
VTVT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest vTv Therapeutics Inc. (VTVT) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How VTVT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Type 1 Diabetes #6 of 19 PHASE 3 Cadisegliatin
LLY NVO SNY
$3.5B 0.9 CONTENDER